Erlotinib complexation with randomly methylated β-cyclodextrin improves drug solubility, intestinal permeability, and therapeutic efficacy in non-small cell lung cancer
… The purpose of this study was to investigate the impact of anticancer drug erlotinib-randomly …
Phase solubility study showed erlotinib displayed maximum solubility in RAMEB CD …
Phase solubility study showed erlotinib displayed maximum solubility in RAMEB CD …
Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer
K Lee, Y Kim, HA Jung, SH Lee, JS Ahn, MJ Ahn… - Lung cancer, 2019 - Elsevier
… Therefore, our study could not include any … , our study is the first comparative analysis for
T790 M mutation rates as a resistance mechanism between afatinib and gefitinib or erlotinib. …
T790 M mutation rates as a resistance mechanism between afatinib and gefitinib or erlotinib. …
Erlotinib loaded chitosan nanoparticles: Formulation, physicochemical characterization and cytotoxic potential
… study was to prepare and evaluate erlotinib loaded chitosan nanoparticles for their anticancer
potential. Also, to study the … Erlotinib loaded chitosan nanoparticles were prepared by ionic …
potential. Also, to study the … Erlotinib loaded chitosan nanoparticles were prepared by ionic …
Cost-effectiveness analysis of afatinib, erlotinib, and gefitinib as first-line treatments for EGFR mutation-positive non-small-cell lung cancer in Ontario, Canada
… The results of the present study demonstrated that erlotinib was dominated by afatinib and
gefitinib, while afatinib had an ICER estimate of $34,879 per LY gained or $46,506 per QALY …
gefitinib, while afatinib had an ICER estimate of $34,879 per LY gained or $46,506 per QALY …
An in silico design of bioavailability for kinase inhibitors evaluating the mechanistic rationale in the CYP metabolism of erlotinib
SM Chelli, P Gupta, SK Belliraj - Journal of Molecular Modeling, 2019 - Springer
… In this context, we hypothesized a mechanistic rationale for metabolism of erlotinib by the
CYP3A4 enzyme. The comparison of the 3D conformations of the target CYP class of enzymes …
CYP3A4 enzyme. The comparison of the 3D conformations of the target CYP class of enzymes …
Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
X Gu, Q Zhang, YB Chu, YY Zhao, YJ Zhang, D Kuo… - Lung Cancer, 2019 - Elsevier
… depends on their comparative costs and effectiveness. The primary objective of this study is
to … chemotherapy and other EGFR-TKIs (gefitinib and erlotinib) for the first-line treatment of …
to … chemotherapy and other EGFR-TKIs (gefitinib and erlotinib) for the first-line treatment of …
[HTML][HTML] Nicotine induces resistance to erlotinib therapy in non-small-cell lung cancer cells treated with serum from human patients
T Imabayashi, J Uchino, H Osoreda, K Tanimura… - Cancers, 2019 - mdpi.com
… Although both components are considered to contribute to the resistance to EGFR-TKI, further
investigation with a comparative study on which components contribute the most needs to …
investigation with a comparative study on which components contribute the most needs to …
RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non–small cell lung cancer
…, M Reck, RELAY study investigators - Clinical Cancer …, 2021 - AACR
… -line treatment of EGFRm NSCLC, ramucirumab plus erlotinib (RAM+ERL) showed a consistent
PFS treatment benefit compared with placebo plus erlotinib (PBO+ERL) among patients …
PFS treatment benefit compared with placebo plus erlotinib (PBO+ERL) among patients …
[HTML][HTML] Influence of rutin, sinapic acid, and naringenin on binding of tyrosine kinase inhibitor erlotinib to bovine serum albumin using analytical techniques along with …
… This study evaluated the interactions of rutin (RUT), naringenin (NAR), and sinapic acid (SIN…
the anticancer drug, the tyrosine kinase inhibitor Erlotinib (ETB), using various analytical …
the anticancer drug, the tyrosine kinase inhibitor Erlotinib (ETB), using various analytical …
[HTML][HTML] Clinical efficacy and safety of erlotinib combined with chemotherapy in the treatment of advanced pancreatic cancer: A meta-analysis
XY Liu, HN Pan, Y Yu - World Journal of Gastrointestinal Surgery, 2024 - ncbi.nlm.nih.gov
… Nevertheless, the results of this study showed that erlotinib combined with chemotherapy
significantly prolonged the PFS of pancreatic cancer patients compared with chemotherapy …
significantly prolonged the PFS of pancreatic cancer patients compared with chemotherapy …